source
- Hims sales dip as telehealth rivals intensify; Bristol partners with Chinese firm, other biotech updatesHims reported lower sales this quarter, attributing the shortfall to growing competition from other telehealth providers. Bristol announced a new partnership with Chinese drugmaker Hengrui Pharma…
- Capsida Biotherapeutics still unable to determine cause of child death in brain-targeted gene therapy trialCapsida Biotherapeutics reported that it still has no explanation for the death of a child who participated in its CAP-002 gene therapy trial last September. The trial was intended to test a new c…